Press Release Archive

02.24.2014

Pfizer Announces FDA Approval To Include Radiographic Data On Reduction Of Progression Of Structural Joint Damage For Adults With Moderately To Severely Active Rheumatoid Arthritis In Labeling For XELJANZ® (tofacitinib citrate)

02.24.2014

Pfizer Announces Positive Top-Line Results Of Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA) Evaluating Efficacy Of Prevenar 13*

02.21.2014

In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events Versus Warfarin Consistently Across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation[i]

02.15.2014

Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies

02.11.2014

Pfizer Statement on Today’s Joint Meeting of FDA Advisory Committees

02.11.2014

New Funding For Fundamental Biomedical Research To Be Made Available

02.05.2014

Ichor Enters Into An Agreement With Pfizer To Develop Electroporation Devices For Use In Therapeutic Cancer Vaccine Regimens

02.05.2014

Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies

02.03.2014

Pfizer Announces Positive Top-Line Results From PALOMA-1 Evaluating Palbociclib Plus Letrozole in Women with Advanced Breast Cancer

01.28.2014

U.Va. Spinoff Neoantigenics Announces Collaboration with Pfizer, Investment from CIT to Develop Antibody-based Therapeutics For Cancer

01.28.2014

Pfizer Reports Fourth-Quarter and Full-Year 2013 Results; Provides 2014 Financial Guidance

01.27.2014

Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer